Benzinga FDA Fast-Tracks Vanda's Motion Sickness Drug Review After Leadership Shake-Up
FDA accelerates re-review of Vanda's tradipitant and begins label talks, keeping its motion sickness drug on track for key 2025 decisions. read more
FDA accelerates re-review of Vanda's tradipitant and begins label talks, keeping its motion sickness drug on track for key 2025 decisions. read more